The Occurrence of Metabolic Risk Factors Stratified by Psoriasis Severity: A Swedish Population-Based Matched Cohort Study

References

• Christophers E. Psoriasis− epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26(4):314–320. doi:10.1046/j.1365-2230.2001.00832.x11422182
   PubMed Web of Science ®Google Scholar
• Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Clin Investig Dermatol. 2013;133(2):377–385. doi:10.1038/jid.2012.339
   Google Scholar
• Alexander E, Pinto J, Pal GS, Kamath N, Kuruvilla M. Disease concomitance in psoriasis: a clinical study of 61 cases. Indian J Dermatol Venereol Leprol. 2001;67(2):66–68.17664710
   PubMedGoogle Scholar
• Gelfand JM, Dommasch ED, Shin DB, et al. The risk of stroke in patients with psoriasis. J Clin Investig Dermatol. 2009;129(10):2411–2418. doi:10.1038/jid.2009.112
   Google Scholar
• Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735–1741. doi:10.1001/jama.296.14.173517032986
   PubMed Web of Science ®Google Scholar
• Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol. 1995;32(6):982–986. doi:10.1016/0190-9622(95)91336-X7751469
   PubMed Web of Science ®Google Scholar
• Kimball AB, Guerin A, Latremouille-Viau D, et al. Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis. Am J Med. 2010;123(4):350–357. doi:10.1016/j.amjmed.2009.08.02220362755
   PubMed Web of Science ®Google Scholar
• Kimball AB, Wu Y. Cardiovascular disease and classic cardiovascular risk factors in patients with psoriasis. Int J Dermatol. 2009;48(11):1147–1156. doi:10.1111/j.1365-4632.2009.04075.x20064165
   PubMed Web of Science ®Google Scholar
• Mallbris L, Granath F, Hamsten A, Stahle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol. 2006;54(4):614–621. doi:10.1016/j.jaad.2005.11.107916546581
   PubMed Web of Science ®Google Scholar
• Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta. 2001;303(1–2):33–39. doi:10.1016/S0009-8981(00)00358-211163020
   PubMed Web of Science ®Google Scholar
• Shelling ML, Federman DG, Prodanovich S, Kirsner RS. Psoriasis and vascular disease: an unsolved mystery. Am J Med. 2008;121(5):360–365. doi:10.1016/j.amjmed.2008.01.02518456026
   PubMed Web of Science ®Google Scholar
• Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2007;298(7):321. doi:10.1007/s00403-006-0703-z
   Web of Science ®Google Scholar
• Mehta NN, Yu Y, Pinnelas R, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med. 2011;124(8):775. e771–775. e776. doi:10.1016/j.amjmed.2011.03.028
   Web of Science ®Google Scholar
• Lee M-S, Lin R-Y, Lai M-S. Increased risk of diabetes mellitus in relation to the severity of psoriasis, concomitant medication, and comorbidity: a nationwide population-based cohort study. J Am Acad Dermatol. 2014;70(4):691–698. doi:10.1016/j.jaad.2013.11.02324411084
   PubMed Web of Science ®Google Scholar
• Prodanowich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol. 2005;52(2):262–267. doi:10.1016/j.jaad.2004.06.01715692471
   PubMed Web of Science ®Google Scholar
• Wu JJ, Poon K-YT. Association of gender, tumor necrosis factor inhibitor therapy, and myocardial infarction risk in patients with psoriasis. J Am Acad Dermatol. 2013;69(4):650–651. doi:10.1016/j.jaad.2013.04.03524034374
   PubMed Web of Science ®Google Scholar
• Wu JJ, Poon K-YT, Channual JC, Shen AY-J. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. 2012;148(11):1244–1250. doi:10.1001/archdermatol.2012.250222911151
   PubMed Web of Science ®Google Scholar
• Ryan C, Korman NJ, Gelfand JM, et al. Research gaps in psoriasis: opportunities for future studies. J Am Acad Dermatol. 2014;70(1):146–167. doi:10.1016/j.jaad.2013.08.04224126079
   PubMed Web of Science ®Google Scholar
• Hajiebrahimi M, Linder M, Hägg D, et al. Young patients with risk factors prevalent in the elderly–differences in comorbidity depending on severity of psoriasis: a nationwide cross-sectional study in Swedish health registers. Clin Epidemiol. 2018;10:705. doi:10.2147/CLEP.S16491829950900
   PubMed Web of Science ®Google Scholar
• Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11(1):1. doi:10.1186/1471-2458-11-45021199570
   PubMed Web of Science ®Google Scholar
• Scocialstyrelsen. Swedish Cause of Death Register 2017.
   Google Scholar
• Wettermark B, Hammar N, MichaelFored C, et al. The new Swedish Prescribed Drug Register—opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16(7):726–735. doi:10.1002/pds.129416897791
   PubMed Web of Science ®Google Scholar
• Hultcrantz M, Björkholm M, Dickman PW, et al. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study. Ann Intern Med. 2018;168(5):317–325. doi:10.7326/M17-002829335713
   PubMed Web of Science ®Google Scholar
• Ma L, Li M, Wang H, Li Y, Bai B. High prevalence of cardiovascular risk factors in patients with moderate or severe psoriasis in northern China. Arch Dermatol Res. 2014;306(3):247–251. doi:10.1007/s00403-013-1437-324385235
   PubMed Web of Science ®Google Scholar
• Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55(5):829–835. doi:10.1016/j.jaad.2006.08.04017052489
   PubMed Web of Science ®Google Scholar
• Kaye J, Li L, Jick S. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol. 2008;159(4):895–902. doi:10.1111/j.1365-2133.2008.08707.x18616778
   PubMed Web of Science ®Google Scholar
• Egeberg A, Gyldenlove M, Zachariae C, Skov L. Validation of psoriasis severity classification based on use of topical or systemic treatment. J Eur Acad Dermatol Venereol. 2018;32(1):e4–e5. doi:10.1111/jdv.1442728646609
   PubMed Web of Science ®Google Scholar
• Loft N, Skov L, Bryld LE, Gislason G, Egeberg A. Treatment history of patients receiving biologic therapy for psoriasis – a Danish nationwide study. J Eur Acad Dermatol Venereol. 2017;31(8):e362–e363. doi:10.1111/jdv.1415628168750
   PubMed Web of Science ®Google Scholar